Home/Filings/4/0001437749-16-042844
4//SEC Filing

RESPONSE BIOMEDICAL CORP 4

Accession 0001437749-16-042844

CIK 0000806888operating

Filed

Nov 30, 7:00 PM ET

Accepted

Dec 1, 9:14 PM ET

Size

22.1 KB

Accession

0001437749-16-042844

Insider Transaction Report

Form 4
Period: 2016-11-29
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2016-11-295,0000 total
    Exercise: $1.43Exp: 2024-03-19Common Stock (5,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2016-11-295,0000 total
    Exercise: $0.92Exp: 2025-03-19Common Stock (5,000 underlying)
  • Award

    Common Stock

    2016-11-29+50,154135,671 total
  • Disposition to Issuer

    Common Stock

    2016-11-29135,6710 total
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2016-11-2920,0000 total
    Exercise: $2.20Exp: 2022-04-02Common Stock (20,000 underlying)
  • Award

    Deferred Share Unit

    2016-11-2950,1540 total
    Common Stock (50,154 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2016-11-2920,0000 total
    Exercise: $3.10Exp: 2023-03-14Common Stock (20,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2016-11-295,0000 total
    Exercise: $0.85Exp: 2025-12-21Common Stock (5,000 underlying)
Holdings
  • Warrant

    Exercise: $1.42From: 2011-12-29Exp: 2016-12-29Common Stock (24,650 underlying)
    24,650
Footnotes (12)
  • [F1]Each deferred share unit represent a right to receive shares of Company common stock (or, in the sole discretion of the Issuer's Board of Directors following a Change in Control as defined in the Plan, cash, securities or a combination of cash and securities equal to the fair market value thereof) upon the reporting person's termination of service to the Company. The DSUs are immediately vested and expire 90-days following the reporting person's Termination Date as defined in the Plan.
  • [F10]Subject to the reporting person's continued service as a director of the company through each vesting date, 100% of the shares subject to the option shall vest and become exercisable on March 24, 2017.
  • [F11]The warrants expire five years from the date of issue.
  • [F12]In connection with the Arrangement, all outstanding warrants to purchase shares of the issuers common stock will remain exercisable in accordance with their terms.
  • [F2]Prices shown are denominated in Canadian dollars.
  • [F3]Disposed of pursuant to the Agreement and Plan of Arrangement by and between the issuer and 1077801 B.C. Ltd., dated June 16, 2016 (the "Arrangement"), pursuant to which 1077801 B.C. Ltd. acquired all of the outstanding common shares of the issuer (other than those rolled over into the purchaser) in exchange for cash consideration of $1.12 CDN per share.
  • [F4]100% of the options vest fully on the date which is one year after the date of grant.
  • [F5]Pursuant to the terms of the Arrangement, out of money stock options were cancelled.
  • [F6]100% of the options vest on March 20, 2016, subject to the reporting person's continued service as a director of the Company through each vesting date.
  • [F7]In connection with the Arrangement, all outstanding options to purchase common shares of the issuer as of immediately prior to the effective time of the Arrangement, were deemed unconditionally vested and exercisable, and subsequently cancelled in exchange for cash payment equal to the difference between the per share consideration of $1.12 CDN and the per share exercise price of such option multiplied by the number of common shares issuable pursuant to such option, less applicable withholdings.
  • [F8]The shares subject to the award vest and become exercisable upon termination of the reporting persons service to the Company.
  • [F9]In connection with the Arrangement, all outstanding deferred share units as of immediately prior to the effective time of the Arrangement were converted into common shares of the issuer on a one-for-one basis, and subsequently disposed of in exchange for cash consideration of $1.12 CDN per share pursuant to the terms of the Arrangement Agreement.

Issuer

RESPONSE BIOMEDICAL CORP

CIK 0000806888

Entity typeoperating
IncorporatedBritish Columbia, Canada

Related Parties

1
  • filerCIK 0000806888

Filing Metadata

Form type
4
Filed
Nov 30, 7:00 PM ET
Accepted
Dec 1, 9:14 PM ET
Size
22.1 KB